Calamos Advisors LLC Has $3.08 Million Stake in Tarsus Pharmaceuticals, Inc. $TARS

Calamos Advisors LLC boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 27.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,832 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Calamos Advisors LLC’s holdings in Tarsus Pharmaceuticals were worth $3,075,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after buying an additional 127,470 shares during the period. TimesSquare Capital Management LLC raised its position in Tarsus Pharmaceuticals by 24.3% during the fourth quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after buying an additional 64,941 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH raised its position in Tarsus Pharmaceuticals by 19.9% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock valued at $8,995,000 after buying an additional 18,267 shares during the period. D.A. Davidson & CO. purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter worth about $1,493,000. Finally, M&T Bank Corp lifted its stake in Tarsus Pharmaceuticals by 11,730.0% in the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after acquiring an additional 433,424 shares in the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $57.50 on Thursday. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -50.44 and a beta of 0.50. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The company’s fifty day moving average is $62.16 and its 200-day moving average is $67.08.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The company had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. Equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -0.86 EPS for the current fiscal year.

Insider Activity

In other news, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the transaction, the director directly owned 106,786 shares in the company, valued at $6,633,546.32. The trade was a 10.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Farrow sold 14,396 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total transaction of $877,436.20. Following the transaction, the insider owned 56,801 shares of the company’s stock, valued at approximately $3,462,020.95. The trade was a 20.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 39,850 shares of company stock worth $2,452,821. Insiders own 9.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and set a $88.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Finally, Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $90.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.